Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: A gas permeable layer is formed from an ethylene-vinyl alcohol copolymer resin composition comprising an ethylene-vinyl alcohol copolymer (A), a polyolefin (B), and an acid-modified ethylene-?-olefin copolymer (C).

Abstract: A multilayer article comprising at least a first layer of a thermoplastic polyurethane (TPU) resin composition, a second layer of a TPU resin composition and a core layer between the first layer and the second layer, the core layer comprising a barrier resin composition, wherein the barrier resin composition comprises an ethylene vinyl alcohol copolymer (EVOH) (A), a hydroxyl group containing compound (B) having a molecular weight of 200 or less, a ratio of a number of hydroxyl groups in one molecule relative to the molecular weight within a range of form 0.02 to 0.03, and a melting point of from about 23° C. to about 200° C., and a fatty acid metal salt (C), the multilayer article having good elasticity, stretchability and barrier properties suitable for use in chemical suits and gloves.

Abstract: A monolayer film is provided which contains ethylene vinyl alcohol copolymer (EVOH), contamination from dirt and a compatibilizer, that can be used for producing trash bags and the like, as well as a method to successfully recycle fumigation films containing EVOH and contamination from dirt into such a monolayer film.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, Ring A is cycloalkylene or the like, L is single bond or the like, and R is methyl or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R1, R2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR8, and R8 is as defined herein.

Abstract: A multilayer article having at least one layer of an ethylene vinyl alcohol (EVOH) resin composition comprising of an ethylene-vinyl alcohol copolymer, an unmodified ethylene-?-olefin copolymer and acid modified ethylene-?-olefin copolymer as described below, which is suitable for use in making (or as) a storage bag for agricultural products, food, drink, pharmaceutical, cosmetic, industrial chemical, detergent products.

Abstract: There is provided a co-injection-molded multilayer structure having a barrier layer and outer layers laminated on both sides of the barrier layer, wherein the barrier layer is made of a resin composition comprising an ethylene-vinyl alcohol copolymer (A) and an alkali metal salt (B) of a higher fatty acid having a melting point of 250° C. or lower; a content of the alkali metal salt (B) in the barrier layer is 50 to 1500 ppm in terms of metal atoms; and the outer layers are made of a resin composition comprising an unmodified polypropylene (E) and a maleic anhydride-modified polypropylene (F) having a lower melt viscosity than that of the unmodified polypropylene (E). Although it has no adhesive layers, the co-injection-molded multilayer structure exhibits excellent adhesiveness between the barrier layer made of an EVOH resin composition and the outer layer made of a polypropylene resin composition.

Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: The present invention relates to the compound of formula (I) wherein p is 1 or 2, R1 is —CF3 or the like, R2a, R2b, R3a, and R3b are hydrogen atom or the like, X is —C(?O)—or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and wherein at least one of R1, R2 and R3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.

Abstract: A gas permeable layer is formed from an ethylene-vinyl alcohol copolymer resin composition comprising an ethylene-vinyl alcohol copolymer (A), a polyolefin (B), and an acid-modified ethylene-?-olefin copolymer (C).

Abstract: The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: A multilayer article (such as a film) suitable for use as a fumigation barrier, the multilayer article comprising at least one an ethylene vinyl alcohol (EVOH) based barrier layer formed from a resin composition predominantly comprising an EVOH component of one or more specific types of ethylene-vinyl alcohol copolymers as described herein.

Abstract: The present invention relates to the compound of formula (Ia) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Abstract: A multilayer article comprising at least a first layer of a thermoplastic polyurethane (TPU) resin composition, a second layer of a TPU resin composition and a core layer between the first layer and the second layer, the core layer comprising a barrier resin composition, wherein the barrier resin composition comprises an ethylene vinyl alcohol copolymer (EVOH) (A), a hydroxyl group containing compound (B) having a molecular weight of 200 or less, a ratio of a number of hydroxyl groups in one molecule relative to the molecular weight within a range of form 0.02 to 0.03, and a melting point of from about 23° C. to about 200° C., and a fatty acid metal salt (C), the multilayer article having good elasticity, stretchability and barrier properties suitable for use in chemical suits and gloves.